Niagen.
BIOSCIENCE

The world's leading NAD⁺ company on a mission to extend healthspan.

niagenbioscience.com
truniagen.com
niagenplus.com
aboutnad.com

NASDAQ
NAGE

About Us

Founded in 1999 and headquartered in Los Angeles, California, Niagen Bioscience is a global bioscience innovator advancing human healthspan through patent-protected NAD^+ technologies that support cellular resilience and longevity. Niagen Bioscience operates across four complementary verticals:

- **Tru Niagen®** (Consumer Brand)
- **Niagen® Ingredient** (B2B)
- **Niagen Plus™** (Injection and IV)
- **Pharmaceuticals** (Initial focus on Parkinson's Disease and Ataxia Telangiectasia)

Science & Research

- **40+ peer-reviewed clinical publications** on our flagship ingredient, **Niagen®** (nicotinamide riboside, NR)—the safest and most effective method to elevate NAD^+.
- **175+ peer-reviewed preclinical studies** validating mechanisms and efficacy.
- **30+ active clinical trials** across aging, neurodegenerative, metabolic, and cardiovascular applications.

Intellectual Property

90+ issued patents spanning NR, NRT, NAR, NRH, NMN and NMNH.

Scientific Advisory Board

- **Charles Brenner, Ph.D. (Chief Scientific Advisor)** – NAD^+ metabolism pioneer who discovered the vitamin activity of NR. City of Hope.
- **Roger Kornberg, Ph.D. (Chairman)** – Nobel Laureate in Chemistry in 2006. Stanford University.
- **Vilhelm (Will) Bohr, M.D., Ph.D.** – NIH's National Institute on Aging veteran. Formerly led the Laboratory of Molecular Gerontology.
- **Brunie Felding, Ph.D.** – Scripps Research investigator. Breast cancer and NAD+ precursor research focus.
- **Rudolph Tanzi, Ph.D.** – Harvard neuroscientist and Alzheimer's pioneer. One of the top 50 most-cited neuroscientists in the world.
- **Bruce German, Ph.D.** – UC Davis food science expert in milk and precision nutrition.
- **Pinchas Hassy Cohen, M.D.** – Dean at USC Leonard Davis School of Gerontology. Mitochondrial research specialist.

Financial Snapshot (Trailing 12 Months, as of June 30, 2025)

Net Sales (TTM)	**$116.3 M**	**Cash on Hand**	**$60.5 M**
Net Income (TTM)	**$17.7 M**	**Debt**	**$0**
H1 2025 Revenue Growth	**37% YoY**		